MA48803A - Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a - Google Patents

Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a

Info

Publication number
MA48803A
MA48803A MA048803A MA48803A MA48803A MA 48803 A MA48803 A MA 48803A MA 048803 A MA048803 A MA 048803A MA 48803 A MA48803 A MA 48803A MA 48803 A MA48803 A MA 48803A
Authority
MA
Morocco
Prior art keywords
inhibitors
cycles used
merged
merged cycles
cycles
Prior art date
Application number
MA048803A
Other languages
English (en)
Inventor
Pingchen Fan
Christopher W Lange
Rebecca M Lui
Viengkham Malathong
Venkat Reddy Mali
Sreenivas Punna
Rajinder Singh
Hiroko Tanaka
Yibin Zeng
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MA48803A publication Critical patent/MA48803A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Liquid Crystal Substances (AREA)
  • Glass Compositions (AREA)
MA048803A 2017-05-31 2018-05-29 Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a MA48803A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762513010P 2017-05-31 2017-05-31

Publications (1)

Publication Number Publication Date
MA48803A true MA48803A (fr) 2020-04-08

Family

ID=64456009

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048803A MA48803A (fr) 2017-05-31 2018-05-29 Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a

Country Status (13)

Country Link
US (3) US10562896B2 (fr)
EP (1) EP3630775B1 (fr)
JP (1) JP7141130B2 (fr)
KR (1) KR102638253B1 (fr)
CN (1) CN110997674B (fr)
AR (1) AR111983A1 (fr)
AU (1) AU2018277520B2 (fr)
IL (1) IL270828B2 (fr)
MA (1) MA48803A (fr)
MX (1) MX392259B (fr)
TW (1) TWI781177B (fr)
WO (1) WO2018222598A1 (fr)
ZA (1) ZA201907746B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2934507T3 (es) 2017-05-31 2023-02-22 Chemocentryx Inc Anillos fusionados en 5-5 como inhibidores de C5a
JP7141130B2 (ja) 2017-05-31 2022-09-22 ケモセントリックス，インコーポレイティド Ｃ５ａ阻害剤としての６－５融合環
US10828285B2 (en) 2017-12-22 2020-11-10 Chemocentryx, Inc. Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
MX2020006460A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
SG11202009588PA (en) * 2018-04-02 2020-10-29 Chemocentryx Inc PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
WO2021007386A1 (fr) 2019-07-10 2021-01-14 Chemocentryx, Inc. Indanes en tant qu'inhibiteurs de pd-l1
CN112625036A (zh) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 一类具有brd4抑制活性的化合物、其制备方法及用途
BR112022006279A2 (pt) 2019-10-16 2022-06-28 Chemocentryx Inc Heteroaril-bifenil aminas para o tratamento de doenças pd-l1
AU2020368393B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
US12577240B2 (en) 2020-07-11 2026-03-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US20220047592A1 (en) * 2020-08-13 2022-02-17 Chemocentryx, Inc. METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
WO2022093971A1 (fr) 2020-10-28 2022-05-05 Chemocentryx, Inc. Méthodes de traitement de l'hidradénite suppurée
CN112979646B (zh) * 2021-03-08 2022-01-14 北京富龙康泰生物技术有限公司 一种咪唑并吡啶类衍生物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK27383A (da) 1982-02-17 1983-08-18 Lepetit Spa Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner
GB8613591D0 (en) 1986-06-04 1986-07-09 Roussel Lab Ltd Chemical compounds
FR2761266B1 (fr) 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
KR100904157B1 (ko) 2000-08-10 2009-06-23 파마시아 이탈리아 에스.피.에이. 키나제 억제제로서 활성인 비사이클로-피라졸, 이의제조방법 및 이를 포함하는 약제학적 조성물
ATE404553T1 (de) 2000-09-29 2008-08-15 Neurogen Corp Hochaffine kleinmolekülige c5a-rezeptor- modulatoren
SE524438C2 (sv) 2000-10-05 2004-08-10 Magnus Georg Goertz Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium
US7902179B2 (en) * 2001-04-26 2011-03-08 Ajinomoto Co., Inc. Heterocyclic compounds
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
EP1487798A4 (fr) 2002-03-28 2005-07-13 Neurogen Corp Tetrahydroisoquinoleines substituees servant de modulateurs du recepteur c5a
AU2003225971A1 (en) 2002-03-28 2003-10-13 Yang Gao Substituted biaryl amides as c5a receptor modulators
WO2003084524A1 (fr) 2002-03-29 2003-10-16 Neurogen Corporation Therapie combinatoire pour le traitement de maladies faisant intervenir des composants inflammatoires
AU2003265395A1 (en) * 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
AU2003265625A1 (en) 2002-08-21 2004-03-11 Neurogen Corporation Amino methyl imidazoles as c5a receptor modulators
US7342115B2 (en) 2002-11-08 2008-03-11 Neurogen Corporation 3-substituted-6-aryl pyridines
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
WO2005007087A2 (fr) 2003-07-03 2005-01-27 Neurogen Corporation Derives (heterocycloalkyl)methyle substitues de type azole utilises comme modulateurs des recepteurs c5a
US7906528B2 (en) 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
WO2007019083A1 (fr) 2005-08-04 2007-02-15 Janssen Pharmaceutica N.V. Composes de pyrimidine utiles comme modulateurs des recepteurs de la serotonine
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
WO2008024978A2 (fr) 2006-08-24 2008-02-28 Serenex, Inc. Dérivés de benzène, de pyridine et de pyridazine
AU2009259867A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
CN102264227B (zh) 2008-12-22 2014-07-23 凯莫森特里克斯股份有限公司 C5aR拮抗剂
KR20120092096A (ko) 2009-09-02 2012-08-20 머크 샤프 앤드 돔 코포레이션 당뇨병의 치료 또는 예방을 위한 디펩티딜 펩티다제-ｉｖ 억제제로서의 아미노테트라히드로피란
RS56332B1 (sr) 2010-06-24 2017-12-29 Chemocentryx Inc Antagonisti c5ar
US8846656B2 (en) * 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
KR20150042271A (ko) 2012-08-16 2015-04-20 얀센 파마슈티카 엔.브이. N형 칼슘 채널 차단제로서의 치환된 피롤로피라졸
CN103421006B (zh) * 2013-08-18 2016-06-22 上海师范大学 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
AU2017246228B2 (en) 2016-04-04 2021-04-15 Chemocentryx, Inc. Soluble C5aR antagonists
JP7141130B2 (ja) * 2017-05-31 2022-09-22 ケモセントリックス，インコーポレイティド Ｃ５ａ阻害剤としての６－５融合環
ES2934507T3 (es) * 2017-05-31 2023-02-22 Chemocentryx Inc Anillos fusionados en 5-5 como inhibidores de C5a
US10589871B2 (en) 2017-09-25 2020-03-17 Hamilton Sundstrand Corporation Prognostic health monitoring and jam detection for use with an aircraft
MX2020006460A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
US10828285B2 (en) 2017-12-22 2020-11-10 Chemocentryx, Inc. Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
SG11202009588PA (en) 2018-04-02 2020-10-29 Chemocentryx Inc PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS

Also Published As

Publication number Publication date
EP3630775B1 (fr) 2022-12-14
IL270828B2 (en) 2023-04-01
US11773091B2 (en) 2023-10-03
US20200347049A1 (en) 2020-11-05
AU2018277520B2 (en) 2022-03-17
TW201902895A (zh) 2019-01-16
MX392259B (es) 2025-03-24
BR112019025049A2 (pt) 2020-06-16
RU2019142942A3 (fr) 2021-09-03
EP3630775A1 (fr) 2020-04-08
US10562896B2 (en) 2020-02-18
US11384079B2 (en) 2022-07-12
AR111983A1 (es) 2019-09-11
US20180370967A1 (en) 2018-12-27
WO2018222598A1 (fr) 2018-12-06
IL270828B (en) 2022-12-01
US20230151002A1 (en) 2023-05-18
KR20200015604A (ko) 2020-02-12
TWI781177B (zh) 2022-10-21
CN110997674B (zh) 2022-12-20
ZA201907746B (en) 2023-10-25
CA3064017A1 (fr) 2018-12-06
IL270828A (en) 2020-01-30
JP2020522484A (ja) 2020-07-30
KR102638253B1 (ko) 2024-02-16
EP3630775A4 (fr) 2020-10-07
RU2019142942A (ru) 2021-06-30
JP7141130B2 (ja) 2022-09-22
CN110997674A (zh) 2020-04-10
AU2018277520A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
MA48803A (fr) Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA49566A (fr) Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA54076A (fr) 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
EP3873468A4 (fr) 2-amino-n-phényl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA48800A (fr) Cycles 5-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA43862A (fr) Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock
EP3386981A4 (fr) Hétérocycles utiles en tant qu'agents anticancereux
FR25C1047I1 (fr) Aminopyrazoles en tant qu'inhibiteurs sélectifs de janus kinase
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA47086A (fr) Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
EP3733671A4 (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase